TEL AVIV, Israel, Nov. 20, 2023 /PRNewswire/ — Arbe Robotics Ltd. (NASDAQ: ARBE), a global leader in Perception Radar Solutions, announced today that Cars of the Future awarded the company the Self-Driving Industry 2023 Award in the hardware category. Read more...
Read MoreJERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and HekaBio K.K. (“HekaBio”) a Japan-based healthcare investment, development and commercialization platform which is partnered with Alpha Tau, announced today that Japan’s Pharmaceuticals and Medical Devices Agency (“PMDA”) has accepted Alpha Tau’s submission requesting shonin pre-market approval of Alpha DaRT in patients with recurrent head & neck cancer, following multiple pre-submission consultation meetings with the PMDA per common practice in Japan. This submission is based upon Alpha DaRT’s clinical trial results in Japan which exceeded the target endpoints for safety and efficacy in patients with recurrent head and neck cancer. Read...
Read MoreTEL AVIV, Israel and NEW YORK, Nov. 20, 2023 /PRNewswire/ — BioCatch, the global leader in digital fraud and money laundering detection and response powered by behavioral biometric intelligence, today announced that it has reached Centaur status, surpassing $100m in annual recurring revenue. Read...
Read MoreUrsa Major, the Colorado-based manufacturer of rocket engines produced with additive manufacturing (AM), has unveiled Lynx, the company’s first design and production process for solid rocket motors (SRMs). Given that, in recent history, missile inventories have come to represent the primary application space for SRMs, Lynx is of the utmost relevance to the Department of Defense’s (DoD’s) AM objectives. Read more...
Read MoreJerusalem, November 20, 2023 — Alpha Tau Medical Ltd. (“Alpha Tau”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and HekaBio K.K. (“HekaBio”) a Japan-based healthcare investment, development and commercialization platform which is partnered with Alpha Tau, announced today that Japan’s Pharmaceuticals and Medical Devices Agency (“PMDA”) has accepted Alpha Tau’s submission requesting shonin pre-market approval of Alpha DaRT in patients with recurrent head & neck cancer, following multiple pre-submission consultation meetings with the PMDA per common practice in Japan. This submission is based upon Alpha DaRT’s clinical trial results in Japan which exceeded the target endpoints for safety and efficacy in patients with recurrent head and neck cancer. Read...
Read More
